Comparative Pharmacology
Head-to-head clinical analysis: IGALMI versus LUMIFY PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IGALMI versus LUMIFY PRESERVATIVE FREE.
IGALMI vs LUMIFY PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from the central nervous system, resulting in decreased agitation and sedation.
Selective alpha-1 adrenergic receptor agonist; causes vasoconstriction of conjunctival blood vessels, reducing redness.
Sublingual: 120 mcg to 180 mcg as a single dose, administered under the tongue, one time. Maximum single dose: 180 mcg.
1 drop in each affected eye every 6-8 hours as needed, ophthalmic route.
None Documented
None Documented
Terminal elimination half-life is 2.5 to 3.5 hours in healthy subjects, with prolonged half-life in patients with hepatic impairment (up to 5-7 hours) or renal impairment (up to 6-8 hours).
Terminal elimination half-life is approximately 2-3 hours. Clinical context: Allows for twice-daily dosing for sustained intraocular pressure reduction; steady-state achieved within 2 days.
Approximately 75% of the dose is excreted renally as unchanged drug, with the remainder eliminated via biliary/fecal routes (approximately 20%) and minor metabolic clearance.
Primarily renal excretion of unchanged drug (approx. 60-80%) and metabolites (glucuronide conjugates). Biliary/fecal elimination accounts for <10%.
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist